{"id":"W3215447362","doi":"10.1053/j.gastro.2021.10.051","title":"Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis","year":2021,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Alcohol Abuse and Alcoholism; National Institute of Environmental Health Sciences; NIHR Newcastle Biomedical Research Centre; Sandoz; Genentech; AstraZeneca; Allergan; Inventiva Pharma; Siemens; Novartis Pharma; European Commission; Innovative Medicines Initiative; Intercept Pharmaceuticals; NGM Biopharmaceuticals; Boehringer Ingelheim; Gilead Sciences; Roche; Novo Nordisk; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Arrien Pharmaceuticals; Novartis; GlaxoSmithKline; National Heart, Lung, and Blood Institute; Shire; Bristol-Myers Squibb; Eli Lilly and Company; Horizon 2020; European Federation of Pharmaceutical Industries and Associations; DOD Peer Reviewed Cancer Research Program; Takeda Pharmaceutical Company; Abbott Laboratories","keywords":"Nonalcoholic steatohepatitis; Medicine; Drug; Steatohepatitis; Drug development; Internal medicine; Pharmacology; Nonalcoholic fatty liver disease; Fatty liver","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000154884,0.000458302,0.002457979,0.0001768831,0.00003809151,0.00001469631,0.0000948546,0.00005939595,0.0001012643],"category_scores_gemma":[0.00004283424,0.0003609388,0.0001615244,0.0001077932,0.00004684736,0.00002220001,0.0001904504,0.0001967212,0.00004503002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002170323,"about_ca_system_score_gemma":0.0001287745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005603256,"about_ca_topic_score_gemma":0.0002927989,"domain_scores_codex":[0.9977176,0.0002777419,0.0006799112,0.0007306777,0.0001924101,0.0004016172],"domain_scores_gemma":[0.9990068,0.00008894673,0.0001577651,0.0003612878,0.00004808042,0.0003371264],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007755671,0.0008160468,0.07679304,0.03325452,0.0007098324,0.001820497,0.0004140072,7.456273e-8,9.976716e-8,0.00002029655,0.01228042,0.8738136],"study_design_scores_gemma":[0.001202043,0.0002939504,0.0423539,0.1455278,0.0005893867,0.0004399408,0.00002015157,3.037124e-7,0.000001325508,6.733387e-7,0.8093928,0.0001776969],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01551353,0.9818725,0.00000148457,0.0009273368,0.00009781966,0.001438329,0.00006919133,0.00001450218,0.00006527828],"genre_scores_gemma":[0.0008944081,0.9900293,0.000560244,0.006874109,0.00005636835,0.001109904,0.0003683698,0.00003570551,0.00007157381],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8736359,"threshold_uncertainty_score":0.9998842,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07979963252423165,"score_gpt":0.3579071688042244,"score_spread":0.2781075362799927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}